Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Allergic Conjunctivitis pipeline constitutes 22+ key companies continuously working towards developing 22+ Allergic Conjunctivitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Allergic Conjunctivitis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Allergic Conjunctivitis Market.

The Allergic Conjunctivitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Allergic Conjunctivitis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Allergic Conjunctivitis treatment therapies with a considerable amount of success over the years.

*
Allergic Conjunctivitis companies working in the treatment market are OKYO Pharma, IACTA Pharmaceuticals, VANDA PHARMACEUTICALS, Bausch & Lomb Incorporated, Aldeyra Therapeutics, Inc, Ocular Therapeutix, and others, are developing therapies for the Allergic Conjunctivitis treatment

*
Emerging Allergic Conjunctivitis therapies in the different phases of clinical trials are- OK-101, IC-270, VSJ-110, Brimonidine Tartrate, Reproxalap, Ketotifen fumarate ophthalmic solution, Dextenza, and others are expected to have a significant impact on the Allergic Conjunctivitis market in the coming years.

*
In April 2025, Ocular Therapeutix, Inc. announced the results of a randomized, parallel-arm, active-controlled, multi-center study evaluating the safety and efficacy of Dextenza Registered for treating ocular pain and inflammation after surgery for pediatric cataract.

*
In March 2025, Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), which the FDA has determined to be bioequivalent to Pataday Registered Once Daily Relief Ophthalmic Solution, 0.2% (OTC), by Alcon Laboratories, Inc. Glenmark Therapeutics Inc., USA, will distribute Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) in the U.S. market.

*
In August 2024, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on developing innovative treatments for immune-mediated and metabolic diseases, announced the successful achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled clinical trial of 0.25% reproxalap ophthalmic solution, an investigational drug for treating dry eye disease. Reproxalap demonstrated statistically significant superiority over the vehicle in reducing ocular discomfort (P=0.004), a symptom of dry eye disease recognized by the U.S. Food and Drug Administration (FDA).

Allergic Conjunctivitis Overview

Allergic conjunctivitis is an eye condition characterized by inflammation of the conjunctiva, which is the thin, transparent layer of tissue covering the front surface of the eye and the inner surface of the eyelids. It occurs as a result of an allergic reaction, triggered by exposure to allergens such as pollen, dust mites, pet dander, or certain irritants like smoke or perfume.

Get a Free Sample PDF Report to know more about Allergic Conjunctivitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight [https://www.delveinsight.com/report-store/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Allergic Conjunctivitis Drugs Under Different Phases of Clinical Development Include:

*
OK-101: OKYO Pharma

*
IC-270: IACTA Pharmaceuticals

*
VSJ-110: VANDA PHARMACEUTICALS

*
Brimonidine Tartrate/KetotifenFumarate: Bausch & Lomb Incorporated

*
Reproxalap: Aldeyra Therapeutics, Inc

*
Ketotifen fumarate ophthalmic solution: Bausch & Lomb Incorporated

*
Dextenza: Ocular Therapeutix

Allergic Conjunctivitis Route of Administration

Allergic Conjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Inhalation

*
Inhalation/Intravenous/Oral

*
Intranasal

*
Intravenous

*
Intravenous/ Subcutaneous

*
NA

*
Oral

*
Oral/intranasal/subcutaneous

*
Parenteral

*
Subcutaneous

Allergic Conjunctivitis Molecule Type

Allergic Conjunctivitis Products have been categorized under various Molecule types, such as

*
Antibody

*
Antisense oligonucleotides

*
Immunotherapy

*
Monoclonal antibody

*
Peptides

*
Protein

*
Recombinant protein

*
Small molecule

*
Stem Cell

*
Vaccine

Allergic Conjunctivitis Pipeline Therapeutics Assessment

*
Allergic Conjunctivitis Assessment by Product Type

*
Allergic Conjunctivitis By Stage and Product Type

*
Allergic Conjunctivitis Assessment by Route of Administration

*
Allergic Conjunctivitis By Stage and Route of Administration

*
Allergic Conjunctivitis Assessment by Molecule Type

*
Allergic Conjunctivitis by Stage and Molecule Type

DelveInsight's Allergic Conjunctivitis Report covers around 22+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Allergic Conjunctivitis product details are provided in the report. Download the Allergic Conjunctivitis pipeline report to learn more about the emerging Allergic Conjunctivitis therapies [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Allergic Conjunctivitis Therapeutics Market include:

Key companies developing therapies for Allergic Conjunctivitis are - OKYO Pharma, RAPT Therapeutics, Allakos, Sylentis, Postbiotica, Stuart Therapeutics, Oyster Point Pharma, Bausch Health Companies Inc., Bausch & Lomb Incorporated, Aldeyra Therapeutics, Vanda Pharmaceuticals, Noveome Biotherapeutics, Allakos, Inc., Regeneron Pharmaceuticals, Marinomed Biotech AG, Eleusis Holdings Ltd, IACTA Pharmaceuticals, JW Pharmaceutical, Nanomerics, Marinomed Biotech AG, ILTOO Pharma, Emergo Therapeutics, and others.

Allergic Conjunctivitis Pipeline Analysis:

The Allergic Conjunctivitis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Conjunctivitis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Conjunctivitis Treatment.

*
Allergic Conjunctivitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Allergic Conjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Conjunctivitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Allergic Conjunctivitis drugs and therapies [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Allergic Conjunctivitis Pipeline Market Drivers

*
Increased Prevalence of Allergic Conjunctivitis, recent Advancements in Research and Developmental Activities are some of the important factors that are fueling the Allergic Conjunctivitis Market.

Allergic Conjunctivitis Pipeline Market Barriers

*
However, lack of awareness of the Disease Condition, adverse effects of the current treatment options and other factors are creating obstacles in the Allergic Conjunctivitis Market growth.

Scope of Allergic Conjunctivitis Pipeline Drug Insight

*
Coverage: Global

*
Key Allergic Conjunctivitis Companies: OKYO Pharma, IACTA Pharmaceuticals, VANDA PHARMACEUTICALS, Bausch & Lomb Incorporated, Aldeyra Therapeutics, Inc, Ocular Therapeutix, and others

*
Key Allergic Conjunctivitis Therapies: OK-101, IC-270, VSJ-110, Brimonidine Tartrate, Reproxalap, Ketotifen fumarate ophthalmic solution, Dextenza, and others

*
Allergic Conjunctivitis Therapeutic Assessment: Allergic Conjunctivitis current marketed and Allergic Conjunctivitis emerging therapies

*
Allergic Conjunctivitis Market Dynamics: Allergic Conjunctivitis market drivers and Allergic Conjunctivitis market barriers

Request for Sample PDF Report for Allergic Conjunctivitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/allergic-conjunctivitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Allergic Conjunctivitis Report Introduction

2. Allergic Conjunctivitis Executive Summary

3. Allergic Conjunctivitis Overview

4. Allergic Conjunctivitis- Analytical Perspective In-depth Commercial Assessment

5. Allergic Conjunctivitis Pipeline Therapeutics

6. Allergic Conjunctivitis Late Stage Products (Phase II/III)

7. Allergic Conjunctivitis Mid Stage Products (Phase II)

8. Allergic Conjunctivitis Early Stage Products (Phase I)

9. Allergic Conjunctivitis Preclinical Stage Products

10. Allergic Conjunctivitis Therapeutics Assessment

11. Allergic Conjunctivitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Allergic Conjunctivitis Key Companies

14. Allergic Conjunctivitis Key Products

15. Allergic Conjunctivitis Unmet Needs

16 . Allergic Conjunctivitis Market Drivers and Barriers

17. Allergic Conjunctivitis Future Perspectives and Conclusion

18. Allergic Conjunctivitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=allergic-conjunctivitis-pipeline-2025-fda-approvals-therapies-clinical-trials-and-latest-developments-unveiled-by-delveinsight-bausch-lomb-inc-aldeyra-therapeutics-vanda-pharma-okyo-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.